PT  - JOURNAL ARTICLE
AU  - Han Hongya
AU  - Zhou Yujie
AU  - Ma Hanying
AU  - Liu Yuyang
AU  - Shi Dongmei
AU  - Zhao Yingxin
AU  - Liu Xiaoli
AU  - Gao Fei
AU  - Shen Hua
TI  - e0501 1-year clinical outcomes after implantation of sirolimus-eluting stents in patients with coronary artery disease and type 2 diabetes
AID  - 10.1136/hrt.2010.208967.501
DP  - 2010 Oct 01
TA  - Heart
PG  - 156--156
VI  - 96
IP  - Suppl 3
4099  - http://heart.bmj.com/content/96/Suppl_3/156.short
4100  - http://heart.bmj.com/content/96/Suppl_3/156.full
SO  - Heart2010 Oct 01; 96
AB  - Background Drug-eluting stents (DES) have been shown to significantly reduce clinical events and angiographic restenosis in the treatment of coronary artery disease (CAD). We aimed to assess the long-term efficacy and safety of two Sirolimus-Eluting Stents (the biodegradable polymer-coated sirolimus-eluting stents, EXCEL and the polymer-based sirolimus-eluting cobalt-chromium stents, Firebird 2) in the treatment of patients with CAD and Type 2 Diabetes. Methods A total of 320 consecutive patients with coronary artery disease and type 2 diabetes undergoing percutaneous coronary intervention randomised into two groups (EXCEL group, n=158; Firebird 2 group, n=162). Baseline clinical characteristics, procedural success rate and occurrence of major adverse cardiac events (MACE, a composite of death, myocardial infarction or target lesion revascularisation) during follow-up were recorded and compared between the two groups. Results During hospitalisation no patient had complications. At 1 year follow-up, both of the EXCEL group and Firebird 2 group had lower occurrence of cardiac events (1.9% in the Excel group and 1.2% in the Firebird group, p>0.05). Conclusion Implantation of EXCEL stent or Firebird 2 stent for patients with coronary artery disease and type 2 diabetes is safe and can reduce major adverse cardiac events in long-term follow-up.